Pharmacovigilance post-market
Pharma post-market surveillance
What we are observing
Pharma post-market surveillance is regulatorily complex and underserved — classical providers are expensive and slow. Clear gaps emerge for smaller pharma companies.
We see the market, but we do not understand it deeply enough to build it alone.
Status
Strategic option. If experienced pharma domain experts are
interested as co-founders/partners: a conversation via
partner@beherzig-group.ch.